Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors
1 other identifier
observational
200
1 country
1
Brief Summary
Samples of 200 patients with pediatric malignant solid tumors will prospectively be collected. Selected samples are sufficient for next generation sequencing(NGS) and available for follow-up information. Multi-omics techniques such as DNA and RNA panel will be used to study driver genes for the development of malignant solid tumors in children, and to explore the pathogenic mechanism. The aim of this study is to explore new biomarkers for the diagnosis and treatment for childhood malignant solid tumors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 6, 2021
CompletedFirst Submitted
Initial submission to the registry
September 30, 2021
CompletedFirst Posted
Study publicly available on registry
October 13, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 6, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 6, 2023
CompletedOctober 13, 2021
September 1, 2021
1.9 years
September 30, 2021
October 12, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Mutation characteristics of malignant solid tumors in Chinese children.
2021.8-2023.8
Interventions
Next Generation Sequencing
Eligibility Criteria
200
You may qualify if:
- Patients are diagnosed by histology and pathology as pediatric malignant solid tumors (including soft tissue sarcoma, osteosarcoma, pediatric glioma, neuroblastoma, nephroblastoma, retinoblastoma, hepatoblastoma, atypical teratoid/rhabdomymoma, embryonal tumor, etc.);
- Age: \< 18 years old;
- Eastern Cooperative Oncology Group (ECOG) PS score: 0-2, estimated survival \>6 months;
- Complete clinical laboratory examination and pathological examination information of patients;
- Patients can be evaluated on time, and samples can be obtained throughout the whole test process;
- Informed consent signed by the patient or his/her legal representative shall be obtained after the patient is informed of the project;
You may not qualify if:
- As determined by the investigator, the patient had other major diseases that might affect follow-up and short-term survival;
- Any social/psychological problems that the researcher determines are not suitable for the study;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yizhuo Zhanglead
Study Sites (1)
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Related Publications (1)
Lu S, Zhang Y, Zhang W, Huang J, Yang C, Wang J, Gao J, Guo X, Yuan X, Chen S, Sun F, Cheng H, Yao W, Dong K, Guo H, Sun X, Li H, Chen K, Lan H, Zhen Z, Zhu J, Zhang X, Que Y, Yan S, Ma J, Li J, Zhu D, Wang H, Wang S, Zhang Y. Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. JCO Precis Oncol. 2026 Jan;10:e2500428. doi: 10.1200/PO-25-00428. Epub 2026 Jan 14.
PMID: 41533994DERIVED
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- proffesor
Study Record Dates
First Submitted
September 30, 2021
First Posted
October 13, 2021
Study Start
August 6, 2021
Primary Completion
July 6, 2023
Study Completion
August 6, 2023
Last Updated
October 13, 2021
Record last verified: 2021-09
Data Sharing
- IPD Sharing
- Will not share